AlphaCore Capital’s Corcept Therapeutics CORT Stock Holding History

AlphaCore Capital’s Portfolio CORT Stock Details CORT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q3	$390K	Buy	+3,382	New	+$364K	0.01%	954

Other funds holding CORT

Parallel Advisors San Francisco, California $7.42B AUM 27.68% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.92T AUM 36.1% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $551B AUM 33.95% 1-Year Est. Return

Bank of New York Mellon New York $608B AUM 32.77% 1-Year Est. Return

Allspring Global Investments Charlotte, North Carolina $64.1B AUM 28.9% 1-Year Est. Return

Barclays London, United Kingdom $500B AUM 36.84% 1-Year Est. Return

Boston Trust Walden Boston, Massachusetts $12.4B AUM 21.62% 1-Year Est. Return

Principal Financial Group Des Moines, Iowa $195B AUM 21.17% 1-Year Est. Return

Russell Investments Group London, United Kingdom $114B AUM 33.83% 1-Year Est. Return

Granite Investment Partners El Segundo, California $1.84B AUM 35.93% 1-Year Est. Return

AlphaCore Capital's CORT Position: Q3 2026 in Review

AlphaCore Capital opened a new position in Corcept Therapeutics (CORT) in Q3 2026: 3,382 shares worth $390K. The stake represents 0.01% of the portfolio and ranks #954 among its holdings.

216 funds tracked by Wall St. Rank hold CORT as of Q3 2026.

AlphaCore Capital held 3,382 shares of Corcept Therapeutics worth $390K as of Q3 2026.
Corcept Therapeutics was a new AlphaCore Capital position in Q3 2026.
Corcept Therapeutics made up 0.01% of AlphaCore Capital's portfolio in Q3 2026, its #954 holding.
216 funds tracked by Wall St. Rank held Corcept Therapeutics as of Q3 2026.

Based on AlphaCore Capital's 13F filing for Q3 2026, filed 4 Nov 2026.